Top Medical News
Stephen Padilla, 14 hours ago
Sonographic patterns outlined by three guidelines (the 2015 American Thyroid Association [ATA] Management Guidelines, the 2014 British Thyroid Association [BTA] Guidelines for the Management of Thyroid Cancer and the Thyroid Imaging Reporting and Data System TIRADS]) have high sensitivity and negative predictive value (NPV), which are needed for triaging of thyroid nodules for subsequent fine needle aspiration (FNA), according to a Singapore study.
Stephen Padilla, Yesterday
Use of dipeptidyl peptidase-4 (DPP-4), and possibly glucagon-like peptide-1 (GLP-1) receptor agonists, may increase the risk of cholangiocarcinoma in adults with type 2 diabetes (T2D) compared with use of other second- or third-line antidiabetic drugs, but the absolute risk is low, according to a study.
2 days ago
The fasting triglycerides and glucose index is a simple and appropriate measure of metabolic health and cardiometabolic disease risk, a recent China study has shown.
Jairia Dela Cruz, 4 days ago
Treatment with aspirin yields reductions in the risk of serious vascular events, albeit at the expense of increased major bleeding events, in diabetic patients with no evident cardiovascular disease, according to data from the ASCEND Study Collaborative Group.
5 days ago
It appears that only troncoconical cuffs can provide accurate blood pressure (BP) measurement in very obese people since cylindrical cuffs overestimate BP mainly in those with high systolic (S)BP, suggests a new study.
Stephen Padilla, 5 days ago
The mDiabetes intervention is both feasible and acceptable in disseminating knowledge to a large population regarding diabetes and healthy lifestyle, as well as in improving health-seeking behaviour, according to a study in India.
6 days ago
In patients with type 2 diabetes mellitus, one in four of all myocardial infarction (MI) events are silent, characterized as the presence of pathological Q waves in the absence of typical cardiac symptoms, a recent study has shown.
Special Reports
28 Nov 2018
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

31 May 2018
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
05 Apr 2017
At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.
20 Jan 2017
At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
04 Jan 2017
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
Conference Reports
Elvira Manzano, 30 Nov 2018
In what many clinicians believed was a rare breakthrough, the prescription fish oil icosapent ethyl cut the risk of ischaemic events among statin-treated patients with high triglyceride levels and either cardiovascular disease (CVD) or diabetes in the REDUCE-IT* trial, putting fish oil on the front burner.
Saras Ramiya, 29 Nov 2018

The Ministry of Health (MOH), Malaysia continues to strive towards achieving the optimal glycaemic target and reducing the impact of diabetes complications among patients.

Stephen Padilla, 21 Nov 2018
Higher ideal levels of dietary intake, physical activity, smoking, blood pressure (BP), cholesterol and body mass index (BMI) are associated with a dose-dependent lower risk of type 2 diabetes (T2D) for individuals with normal fasting glucose but not impaired fasting glucose, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2018.
21 Nov 2018
Slideshow: Highlights from the American Heart Association (AHA) Scientific Sessions 2018
Elaine Soliven, 21 Nov 2018
Treatment with the SGLT2i* empagliflozin appears to significantly reduce left ventricular mass (LVM) among patients with type 2 diabetes (T2D), according to results of the EMPA-HEART** CardioLink-6 trial presented at AHA 2018.
Pearl Toh, 20 Nov 2018
Coronary revascularization with bypass surgery proves to be superior to drug eluting stents in the long term in preventing all-cause mortality in patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), even 8 years after the procedure, the FREEDOM* Follow-On Study reveals.
Roshini Claire Anthony, 19 Nov 2018

Dapagliflozin reduced the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) who had established or multiple risk factors for atherosclerotic cardiovascular disease (CVD), according to results of the DECLARE-TIMI 58* trial presented at AHA 2018. However, it did not reduce the incidence of major adverse cardiovascular events (MACE)**.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download